Antibody Molecule -  John E. Hopper,  Alfred Nisonoff,  Susan B. Spring

Antibody Molecule (eBook)

eBook Download: PDF | EPUB
2014 | 1. Auflage
558 Seiten
Elsevier Science (Verlag)
978-1-4832-7385-3 (ISBN)
Systemvoraussetzungen
Systemvoraussetzungen
70,95 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
The Antibody Molecule
The Antibody Molecule reviews the literature leading to current knowledge of the structure of immunoglobulins. The book begins by outlining some of the basic structural characteristics of immunoglobulins without citing the references on which the information is based. Separate chapters follow covering the chemical nature of the active site of an antibody molecule and mechanisms of interaction with hapten; the general structural features and properties of the various classes of human immunoglobulin; and amino acid sequences of human and mouse L chains and of human and rabbit H chains. Subsequent chapters deal with the evolution of the immunoglobulin classes; special properties of mouse, guinea pig, rabbit, and horse immunoglobulins; idiotypic specificities of immunglobulins; and the genetic control of antibodies. This book is meant for immunologists who have not personally observed the development of this exciting period in the history of immunology. It will also provide useful supplemental reading for the serious student or investigator who wishes to become familiar with the nature of the antibody molecule, its genetic control, and mode of action.

Front Cover 1
The Antibody Molecule 4
Copyright Page 5
Table of Contents 6
Preface 12
Chapter 1. General Structural Features of Immunoglobulîn Molecules Myeloma Proteins
MYELOMA AND BENCE JONES PROTEINS 28
NOMENCLATURE 31
REFERENCES 31
Chapter 2. Nature of the Active Site of an Antibody Molecule and the Mechanism of Antibody–Hapten Interactions 32
I. INHIBITION OF PRECIPITATION BY HAPTENS AND CHEMICAL MODIFICATION AS PROBES FOR ANTIBODY SPECIFICITY 32
II. SPECIFICITY OF ANTIBODIES TO SYNTHETIC POLYPEPTIDES 47
III. STABILIZATION OF THE ANTIBODY MOLECULE BY INTERACTION WITH HAPTEN 54
IV. INDUCTION OF OPTICAL ACTIVITY IN HAPTEN BOUND TO ANTIBODY 54
V. THE QUESTION OF CONFORMATIONAL CHANGES INDUCED IN ANTIBODIES UPON INTERACTION WITH ANTIGEN OR HAPTEN 55
VI. RATES AND ENERGETIC ASPECTS OF ANTIGEN–ANTIBODY REACTIONS 59
VII. AFFINITY LABELING OF ANTIBODY MOLECULES OR MYELOMA PROTEINS WITH ANTIBODY ACTIVITY 85
REFERENCES 97
Chapter 3. Human Immunoglobulins 102
I. GENERAL STRUCTURAL PROPERTIES 102
II. KAPPA AND LAMBDA CHAINS 106
III. IgG AND ITS SUBCLASSES 108
IV. STRUCTURE AND PROPERTIES OF HUMAN IgM 115
V. STRUCTURE AND PROPERTIES OF HUMAN IgA 121
VI. IgE 129
VII. IgD 135
VIII. ß2-MICROGLOBULIN (ß2m) 140
IX. RHEUMATOID FACTORS 142
REFERENCES 144
Chapter 4. Amino Acid Sequences in Human Immunoglobulins and in Mouse Light Chains 154
I. INTRODUCTION 154
II. NUMBERING SYSTEM 155
III. AMINO ACID SEQUENCES IN HUMAN L CHAINS 156
IV. AMINO ACID SEQUENCES IN L CHAINS OF THE MOUSE 172
V. COMMON EVOLUTIONARY ORIGIN OF . AND . CHAINS OF HUMAN AND MOUSE ORIGIN 179
VI. AMINO ACID SEQUENCES IN RABBIT . CHAINS 179
VII. AMINO ACID SEQUENCES IN HUMAN AND RABBIT H CHAINS 182
VIII. AMINO ACID SEQUENCE OF ß2-MICROGLOBULIN 204
IX. AMYLOIDOSIS 205
X. CARBOHYDRATE IN IMMUNOGLOBULINS 209
REFERENCES 219
Chapter 5. The Three-Dimensional Structure of Immunoglobulins 225
I. X-RAY CRYSTALLOGRAPHY 225
Il. PHYSICOCHEMICAL INVESTIGATIONS RELATING TO THREE-DIMENSIONAL STRUCTURE 246
REFERENCES 253
Chapter 6. Properties and Interactions of the Light and Heavy Chains of Immunoglobulins 256
I. INTRODUCTION 256
II. SEPARATION OF LIGHT AND HEAVY CHAINS 257
III. SOLUBILITY AND CONFORMATIONAL PROPERTIES OF THE ISOLATED CHAINS 259
IV. ANTIBODY ACTIVITY IN ISOLATED CHAINS AND IN RECOMBINANTS OF HEAVY AND LIGHT CHAINS 260
V. INTERACTION OF VL OR CL SEGMENTS OF LIGHT CHAINS WITH INTACT HEAVY CHAINS 269
VI. STABILITY OF FRAGMENTS CONSISTING ONLY OF V DOMAINS 270
VII. EFFECT OF HAPTEN ON THE STRENGTH OF INTERACTION OF H AND L CHAINS 271
VIII. CONTRIBUTION TO ANTIBODY ACTIVITY OF ISOLATED H AND L CHAINS 272
IX. HALF-MOLECULES OF IgG 277
REFERENCES 279
Chapter 7. Evolution of the Immunoglobulins 282
I. INTRODUCTION 282
II. UNIVERSALITY OF IgM-LIKE MOLECULES IN VERTEBRATES 285
III. IMMUNOGLOBULINS OF FISH 287
IV. IMMUNOGLOBULINS OF AMPHIBIA 304
V. IMMUNOGLOBULINS OF REPTILES 307
VI. IMMUNOGLOBULINS OF BIRDS APPEARANCE OF IgA
VII. CARBOHYDRATE CONTENT OF IMMUNOGLOBULINS FROM VARIOUS SPECIES ON THE PHYLOGENETIC SCALE 311
VIII. PHYLOGENY OF IgA, IgE, IgG SUBCLASSES, LIGHT CHAIN TYPES, AND THE VHIII SUBGROUP 312
IX. SELECTIVE ADVANTAGES IN THE EVOLUTION OF IMMUNOGLOBULIN CLASSES 324
REFERENCES 326
Chapter 8. Immunoglobulins of the Rabbit, Mouse, Guinea Pig, and Horse 331
I. INTRODUCTION 331
II. GENERAL CONSIDERATIONS 331
III. ANTIGENIC RELATIONSHIPS 336
IV. HOMOCYTOTROPIC ANTIBODIES: IgE 337
V. RABBIT IMMUNOGLOBULINS 339
VI. GUINEA PIG IMMUNOGLOBULINS 350
VII. MOUSE IMMUNOGLOBULINS 351
VIII. HORSE IMMUNOGLOBULINS 355
IX. PASSIVE CUTANEOUS ANAPHYLACTIC REACTIONS IN GUINEA PIGS MEDIATED BY HETEROLOGOUS IMMUNOGLOBULINS 357
REFERENCES 358
Chapter 9. Allotypes of Rabbit, Human, and Mouse Immunoglobulins 364
I. INTRODUCTION 364
II. RABBIT ALLOTYPES 365
III. HUMAN ALLOTYPES 388
IV. MOUSE ALLOTYPES 406
V. SUPPRESSION OF ALLOTYPIC SPECIFICITIES 415
REFERENCES 418
Chapter 10. Homogeneous Antibodies and Myeloma Proteins with Antibody Activity 425
I. INTRODUCTION 425
II. HOMOGENEOUS ANTISTREPTOCOCCAL ANTIBODIES 429
III. HOMOGENEOUS ANTIBODIES TO PNEUMOCOCCAL POLYSACCHARIDES 431
IV. HOMOGENEOUS ANTIHAPTEN ANTIBODIES 432
V. RELATIONSHIP OF STRUCTURE OF ANTIGEN TO THE DEGREE OF HETEROGENEITY OF ANTIBODY 434
VI. RESTRICTED HETEROGENEITY OF HUMAN ANTIBODIES TO POLYSACCHARIDE ANTIGENS 435
VII. INFLUENCE OF GENETIC FACTORS ON THE MAGNITUDE OF THE RESPONSE OF RABBITS TO STREPTOCOCCAL ANTIGENS 436
VIII. INFLUENCE OF GENETIC FACTORS ON THE HETEROGENEITY OF RABBIT ANTIBODIES PRODUCED AGAINST STREPTOCOCCAL ANTIGENS 437
IX. AMINO ACID SEQUENCES OF HOMOGENEOUS RABBIT ANTIBODIES 438
X. COLD AGGLUTININS FROM PATIENTS WITH CHRONIC COLD HEMAGGLUTININ SYNDROME (CHS) 438
XI. RHEUMATOID FACTORS AND CRYOGLOBULINS 441
XII. HUMAN MONOCLONAL PROTEINS WITH ANTIBODY ACTIVITY TOWARD ANTIGENS OTHER THAN IgG 446
XIII. MOUSE MYELOMA PROTEINS WITH ANTIBODY ACTIVITY 450
XIV. SUMMARY OF EVIDENCE RELATING MYELOMA PROTEINS WITH SPECIFIC BINDING ACTIVITY TO INDUCED ANTIBODIES 454
XV. UNUSUAL IMMUNOLOGICAL CROSS-REACTIONS 455
XVI. ANTIBODY ACTIVITY IN CRYSTALLIZED Fab' FRAGMENTS 457
XVII. INDUCTION OF HOMOGENEOUS ANTIBODY AFTER ADOPTIVE TRANSFER OF LIMITED NUMBERS OF CELLS 457
REFERENCES 458
Chapter 11. Idiotypic Specificities of Immunoglobulins 462
I. INTRODUCTION 462
II. IDIOTYPIC SPECIFICITIES IN HUMAN MONOCLONAL PROTEINS 466
III. IDIOTYPIC SPECIFICITIES IN RABBIT AND HUMAN ANTIBODY POPULATIONS 471
IV. IDIOTYPIC CROSS-REACTIONS AMONG RABBIT ANTIBODIES 476
V. IDIOTYPIC CROSS-REACTIONS AMONG ANTIBODIES AND MYELOMA PROTEINS OF INBRED MICE 480
VI. EVIDENCE BASED ON IDIOTYPIC SPECIFICITY FOR LIMITED HETEROGENEITY OF NORMAL ANTIBODY POPULATIONS 488
VII. PERSISTENCE AND CHANGES OF ANTIBODY POPULATIONS DURING PROLONGED IMMUNIZATION 489
VIII. SHARED IDIOTYPIC DETERMINANTS IN RABBIT ANTIBODIES OR HUMAN MYELOMA PROTEINS BELONGING TO DIFFERENT CLASSES 495
IX. LOCALIZATION OF IDIOTYPIC DETERMINANTS 499
X. CROSS-REACTIONS OF ANTIIDIOTYPIC ANTIBODIES WITH NONSPECIFIC IMMUNOGLOBULINS 504
XI. SUPPRESSION OF IDIOTYPIC SPECIFICITIES 506
XII. PRODUCTION OF ANTIIDIOTYPIC ANTIBODIES WITHIN THE SAME STRAIN OF MOUSE ANTITUMOR ACTIVITY OF ANTIMYELOMA PROTEIN ANTIBODIES
XIII. PRODUCTION OF ANTIIDIOTYPIC ANTIBODIES BY AN ANIMAL AGAINST ITS OWN ANTIBODIES 510
REFERENCES 510
Chapter 12. Theories of the Genetic Control of Diversity of Antibodies 515
I. INTRODUCTION 515
II. RNA–DNA HYBRIDIZATION 516
III. BASIC PREMISES RELEVANT TO THEORIES OF ANTIBODY DIVERSITY 519
IV. THEORIES OF ANTIBODY DIVERSITY 530
V. STRENGTHS AND WEAKNESSES OF THE VARIOUS THEORIES 535
VI. REPEATED OCCURRENCE OF MONOCLONAL PROTEINS WITH IDENTICAL V REGIONS 544
REFERENCES 546
Index 551

1

General Structural Features of Immunoglobulin Molecules; Myeloma Proteins


Publisher Summary


This chapter discusses the structure of immunoglobulins. Immunoglobulins are present throughout the vertebrate kingdom but have not been identified in invertebrates. A basic feature, maintained during evolution, is the four-chain structure, comprising two light (L) and two heavy (H) chains. Both the H and L chain contribute amino acid residues that form the antigen-binding site. Each H–L pair produces one binding site, and the four-chain structure thus yields two sites. An individual molecule normally contains one species of H chain and one species of L chain, so that the combining sites of a molecule are identical. This property has its origin in the expression of only one gene for an L chain (variable region) and of one gene for the H chain (variable region) in a lymphoid cell that is synthesizing antibody. An immunoglobulin molecule may have more than four chains. Such molecules are polymers of the four-chain unit, which are held together by disulfide bonds.

One purpose of this text is to review the literature leading to our current knowledge of the structure of immunoglobulins. In subsequent chapters, references are provided to much of the pertinent research. In this introductory section we will outline some of the basic structural characteristics of immunoglobulins without citing the references on which the information is based. The discussion will be brief and, at times, sketchy. Its purpose is to facilitate reading of the remainder of the book, and perhaps to permit the reading of other chapters without strict regard to their sequence.

Immunoglobulins are present throughout the vertebrate kingdom but have not been identified in invertebrates. A basic feature, maintained during evolution, is the four-chain structure, comprising two light (L) and two heavy (H) chains. Both the H and L chain contribute amino acid residues which form the antigen-binding site. Each H-L pair produces one binding site, and the four-chain structure thus yields two sites. An individual molecule normally contains one species of H chain and one species of L chain, so that the combining sites of a molecule are identical. This property has its origin in the expression of only one gene for an L chain (variable region) and of one gene for the H chain (variable region) in a lymphoid cell that is synthesizing antibody.

An immunoglobulin molecule may have more than four chains. Such molecules are polymers of the four-chain unit, which are held together by disulfide bonds. For example, molecules of the IgM class may have from 16 to 24 chains (4–6 four-chain units, or 8–12 potential binding sites), depending on the animal species. Serum IgA may also exist as a polymer, and secretory IgA, found in colostrum, tears, saliva, and other secretory fluids, generally occurs as a dimer of the four-chain unit.

Thus the minimum “valence” of an immunoglobulin is 2. The presence of more than one combining site on the antibody molecule is of biological importance because it permits aggregation of macromolecular or particulate antigens. Bivalence is essential for enhancement of phagocytosis by antibody and for fixation of complement in the presence of antigen. Also, bivalent or multivalent attachment of a single antibody molecule to a particle increases the energy of interaction or “avidity”; this is significant, for example, in the neutralization of viruses, particularly when the affinity of a single combining site is low, as is often the case early in the process of immunization.

It was demonstrated by R.R. Porter in 1958 that cleavage of rabbit IgG by papain at neutral pH gives rise to large fragments with distinctive properties. The nature of this cleavage, as it applies to rabbit IgG or human IgG1, is illustrated in Figs. 1.1 and 1.2. Papain selectively attacks each H chain at a site just N-terminal to the interheavy chain disulfide bonds. This liberates three large fragments. Two are called Fab fragments (ab for antigen-binding) and the other is fragment Fc (c for crystallizable). Each Fab fragment (mol. wt. 45,000) has one antigen-binding site, i.e., is univalent. Fab fragments therefore cannot precipitate macromolecular antigens or agglutinate particulate antigens, but they can, when present in excess, block the precipitation or agglutination that would otherwise occur upon addition of untreated, bivalent antibody. The fragments do this by occupying antigenic determinants, thus denying access to bivalent antibodies. Each Fab fragment comprises a complete L chain and the N-terminal half of an H chain, designated fragment Fd. The L chain and fragment Fd are held together by noncovalent bonds and by a disulfide bond.


Fig. 1.1 Schematic diagram of the arrangement of polypeptide chains and interchain disulfide bonds in rabbit IgG [after Fleischman et al. (2)]. Reduction of the interchain disulfide bonds does not result in a decrease in molecular weight at neutral pH, owing to noncovalent interactions (shaded regions). A more accurate model would show the two L chains as being in very close proximity in the region of the interheavy chain disulfide bond, since in some immunoglobulins the L chains are disulfide bonded to one another. The molecule is flexible; the Fab fragments can rotate relative to one another around the “hinge region,” which includes the sites of cleavage by papain and pepsin.

Fig. 1.2 Schematic diagram of the arrangement of polypeptide chains in human IgG1.

The third fragment, Fc (mol. wt. 50,000), crystallizes spontaneously in cold neutral buffer from a digest of rabbit IgG, which is heterogeneous. Crystallizability is generally associated with homogeneity and this was the first evidence for the presence of an invariant segment in the heterogeneous IgG molecules. We know now that fragment Fc consists of the C-terminal halves of two H chains, which are held together by noncovalent interactions.

Figures 1.1 and 1.2 also show the site of attack of rabbit or human IgG by pepsin at pH 4 to 4.5. Owing to the fact that its preferential site of cleavage is on the C-terminal, rather than the N-terminal side of the interheavy chain disulfide bond(s), a large bivalent fragment is liberated. Only the interheavy chain disulfide bond(s) join the two univalent fragments after peptic digestion; these bonds are very easily reduced, liberating two univalent fragments, designated Fab′, which are slightly larger than fragment Fab. [The initial product of digestion is F(ab′)2.] The Fab′ segments can be reunited, to form fragment F(ab′)2, by reoxidation of the disulfide bond; this cannot, for obvious reasons, be accomplished with fragment Fab. Pepsin partially degrades fragment Fc, possibly owing to the low pH required for peptic activity.

Because of the susceptibility of a particular region in the middle of the H chain to attack by papain, pepsin, and other enzymes, it is generally thought that this region must be loosely folded. It has been designated the hinge region because the two univalent (Fab) fragments can move in space in relation to one another, and it is believed that the “swivel” is in this region of the chain.

This flexibility permits bivalent attachment of a single antibody to a particulate antigen (horseshoe configuration of the antibody) or, alternatively, the linking of two antigen particles with the antibody stretched out to its maximum length (about 140 Å for IgG). The combining sites are situated at the ends of the bivalent IgG molecule. A single, decavalent IgM molecule can attach itself to a particulate antigen through several combining sites. (Information of this kind is obtained by electron microscopy; the location of the combining site has been confirmed by X-ray crystallography, which also provides information as to the dimensions of the site.)

As indicated in Fig. 1.1, each H chain is joined to an L chain through a disulfide bond. In addition, strong noncovalent bonds serve to link the two chains. The latter can be disrupted by reagents such as 6 M guanidine hydrochloride, 8 M urea, or 1 M propionic acid. If the interchain disulfide bond joining the H to the L chain is first reduced, the chains can be separated on a preparative scale by gel filtration in the solvents mentioned. The chains reassociate as H-L pairs, in quite good yield, if the dissociating solvent is replaced by dialysis against neutral buffer. In the native molecule the H chains are joined to one another through disulfide and noncovalent bonds in the hinge and Fc regions. Under appropriate conditions it is possible to produce half-molecules, each consisting of a complete H chain and a complete L chain.

Besides L and H chains, secretory IgA contains a polypeptide called secretory component, or SC, which has a molecular weight of 65,000 – 70,000 and is bound to the H chains of the molecule. Another component, J chain (J for joining; mol. wt. 15,000), is found in the IgM of many primitive and advanced species, and in polymeric, but not monomeric (four-chain) IgA. J chain is linked to H chains through disulfide bonds. The amino acid sequences and antigenic properties of SC and J chain do not appear to be homologous to those of the immunoglobulin polypeptides; i.e., they do not seem to have a common evolutionary origin.

In humans and in many other species there...

Erscheint lt. Verlag 28.6.2014
Sprache englisch
Themenwelt Sachbuch/Ratgeber Natur / Technik Naturführer
Studium Querschnittsbereiche Infektiologie / Immunologie
Naturwissenschaften
ISBN-10 1-4832-7385-7 / 1483273857
ISBN-13 978-1-4832-7385-3 / 9781483273853
Haben Sie eine Frage zum Produkt?
PDFPDF (Adobe DRM)
Größe: 42,3 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

EPUBEPUB (Adobe DRM)
Größe: 8,2 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich
Antibiotika, Virostatika, Antimykotika, Antiparasitäre Wirkstoffe

von Hans-Reinhard Brodt; Achim Hörauf; Michael Kresken …

eBook Download (2023)
Thieme (Verlag)
164,99
Mit den neuen Preisen vom 1.10.2023

von Peter M. Hermanns; Enrico Schwartz; Katharina von Pannwitz

eBook Download (2023)
Springer Berlin Heidelberg (Verlag)
59,99